Pharmacologic treatments for covid-19 patients

Sofosbuvir/daclatasvir vs Standard care/Placebo


Hospitalized patients

Forest plots
(last update: 2021-12-16)

Summary of findings
(last update: 2022-02-10)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=58

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
ISRCTN21085622
Abbass S, J Med Virol, 2021
Full text
Commentary
Private

Sofosbuvir-Daclatasvir

SOF-RDV

Sofosbuvir-Daclatasvir

Standard care

Standard care

SOF-RDV

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Egypt N=120
Some concerns
Details

Full description

N/A
El-Bendary M, Expert Rev Anti-Infe, 2021
Full text
Commentary
No specific funding

Sofosbuvir-Daclatasvir

Standard care

RCT Outpatients and inpatients with confirmed COVID-19 (asymptomatic-severe) treated by or admitted to 3 centers in Egypt. N=174
Some concerns
Details

Full description

IRCT20200624047908N1
DISCOVER
Mobarak S, J Antimicrob Chemoth, 2021
Full text
Full text
Commentary
Public/non profit

Sofosbuvir-Daclatasvir

Placebo

RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to 19 centers in Iran N=1083
Some concerns
Details

Full description

IRCT20200403046926N1
Roozbeh F, J Antimicrob Chemoth, 2020
Full text
Commentary
Public/non profit

Sofosbuvir-Daclatasvir

Standard care

RCT Outpatients with COVID-19 (mild) treated at a single center in Iran N=60 N/A

Full description

DRKS00022203
Yakoot M, SSRN, 2020
Full text
Commentary
Commentary
Private

Sofosbuvir-Daclatasvir

Standard care

RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Egypt N=89
Some concerns
Details

Full description

IRCT20200128046294N2
Sadeghi A, J Antimicrob Chemoth, 2020
Full text
Commentary
Mixed

Sofosbuvir-Daclatasvir

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Iran N=70
Some concerns
Details

Full description